CHAPTER 7

TIME COURSE OF ANGIPOIETIN-2 RELEASE DURING EXPERIMENTAL HUMAN ENDOTOXEMIA AND SEPSIS

Philipp Kümpers*
Matijs van Meurs*
Sascha David
Grietje Molema
Johan Bijzet
Alexander Lukasz
Frank Biertz
Hermann Haller
Jan G. Zijlstra

Crit Care. 2009
13(3):R64.
(* authors contributed equally)
Abstract

Introduction: Endothelial activation leading to vascular barrier breakdown denotes a devastating event in sepsis. Angiopoietin (Ang)-2, a circulating antagonistic ligand of the endothelial specific Tie2 receptor, is rapidly released from Weibel-Palade bodies and has been identified as a non-redundant gatekeeper of endothelial activation. We aimed to study: the time course of Ang-2 release during human experimental endotoxemia; the association of Ang-2 with soluble adhesion molecules and inflammatory cytokines; and the early time course of Ang-2 release during sepsis in critically ill patients.

Methods: In 22 healthy volunteers during a 24-hours period after a single intravenous injection of lipopolysaccharide (LPS; 4 ng/kg) the following measurement were taken by immuno luminometric assay (ILMA), ELISA, and bead-based multiplex technology: circulating Ang-1, Ang-2, soluble Tie2 receptor, the inflammatory molecules TNF-α, IL-6, IL-8 and C-reactive protein, and the soluble endothelial adhesion molecules intercellular adhesion molecule-1 (ICAM-1), E-selectin, and P-selectin. A single oral dose of placebo or the p38 mitogen activated protein (MAP) kinase inhibitor drug, RWJ-67657, was administered 30 minutes before the endotoxin infusion. In addition, the course of circulating Ang-2 was analyzed in 21 septic patients at intensive care unit (ICU) admission and after 24 and 72 hours, respectively.

Results: During endotoxemia, circulating Ang-2 levels were significantly elevated, reaching peak levels 4.5 hours after LPS infusion. Ang-2 exhibited a kinetic profile similar to early proinflammatory cytokines TNF-α, IL-6, and IL-8. Ang-2 levels peaked prior to soluble endothelial-specific adhesion molecules. Finally, Ang-2 correlated with TNF-α levels ($r = 0.61$, $p = 0.003$), soluble E-selectin levels ($r = 0.64$, $p<0.002$), and the heart rate/mean arterial pressure index ($r = 0.75$, $p<0.0001$). In septic patients, Ang-2 increased in non-survivors only, and was significantly higher compared with survivors at baseline, 24 hours and 72 hours.

Conclusions: LPS is a triggering factor for Ang-2 release in men. Circulating Ang-2 appears in the systemic circulation during experimental human endotoxemia in a distinctive
temporal sequence and correlates with TNF-α and E-selectin levels. In addition, not only higher baseline Ang-2 concentrations, but also a persistent increase in Ang-2 during the early course identifies septic patients with unfavorable outcome.
INTRODUCTION

Microvascular capillary leakage resulting in tissue edema, vasodilation refractory to vasopressors, and increased recruitment of leucocytes denote key features of sepsis-related endothelial-cell activation. During the course of severe sepsis and septic shock, widespread endothelial-cell activation contributes to the initiation and progression of multi-organ failure. Recently, Angiopoitietin-2 (Ang-2) has emerged as a key regulator of endothelial-cell activation. In critically ill patients, Ang-2 increases endothelial permeability and is considered a key molecule in the pathogenesis of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS).

Angiopoietin-1 (Ang-1) and Ang-2 are antagonistic ligands, which bind to the extracellular domain of the Tie2 receptor, which is almost exclusively expressed by endothelial cells. Binding of the agonist Ang-1 to the endothelial Tie2 receptor maintains vessel integrity, inhibits vascular leakage, suppresses inflammatory gene expression, and prevents recruitment and transmigration of leukocytes. In vitro, Ang-2 simultaneously mediates disassembly of cell–cell and cell–matrix contacts, and causes active endothelial cell contraction in a Rho kinase-dependent fashion, followed by massive plasma leakage and loss of vasomotor tone. Furthermore, Ang-2 facilitates up-regulation of Inter-Cellular Adhesion Molecule-1 (ICAM-1), Vascular Cell Adhesion Molecule -1 (VCAM-1), and E-selectin.

In vivo, Ang-2-deficient mice do not exhibit any vascular inflammatory responses in experimental sepsis, and vessels in Ang-1-overexpressing mice are resistant to leakage to inflammatory stimuli. As a Weibel-Palade body-stored molecule (WPB), Ang-2 is rapidly released upon endothelial stimulation and is regarded the dynamic regulator within the Ang/Tie system. Consistently, exceptionally high level of circulating Ang-2 have been detected in critically ill patients with sepsis and sepsis-related organ dysfunction.

Beyond its role as a mediator, Ang-2 has been identified as a promising strong marker of endothelial activation in various diseases. In critically ill septic patients, we recently showed that admission levels of circulating Ang-2, correlates with surrogate markers of tissue hypoxia, disease severity, and is a strong and independent predictor of mortality. However, the exact time course of Ang-2 release during sepsis and the role of...
inflammatory cytokines thereof remain elusive. Furthermore, the tempting sequential concept\textsuperscript{11} of Ang-2 as a primer for excess endothelial adhesion molecule expression in sepsis (e.g. ICAM-1, VCAM-1, and E-selectin) has not been investigated in human sepsis.

To address these issues, we wanted to study (1) the time course of Ang-2 release, and (2) the association of Ang-2 with soluble adhesion molecules and inflammatory cytokines in a graded and well-defined human endotoxemia model. Therefore, we re-measured circulating Ang-2, cytokines, and adhesion molecules in blood samples from a placebo-controlled interventional trial on pharmacologic p38 Mitogen-Activated Protein (MAP) kinase inhibition during experimental human endotoxemia\textsuperscript{20}. Furthermore, we analyzed circulating Ang-2 during a 72 hours time course after ICU admission in septic patients.

Table 7.1. Characteristics of septic ICU patients on admission.

<table>
<thead>
<tr>
<th>CHARACTERISTICS</th>
<th>VALUE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients, no.</td>
<td>21</td>
</tr>
<tr>
<td>Male</td>
<td>8 (38.1%)</td>
</tr>
<tr>
<td>Female</td>
<td>13 (61.9%)</td>
</tr>
<tr>
<td>Age (years, median (min - max))</td>
<td>57 (36 - 72)</td>
</tr>
<tr>
<td>Reason for medical ICU admission</td>
<td></td>
</tr>
<tr>
<td>Pneumonia</td>
<td>12 (57.1%)</td>
</tr>
<tr>
<td>Peritonitis</td>
<td>4 (19.0%)</td>
</tr>
<tr>
<td>Urinary tract infection</td>
<td>2 (9.5%)</td>
</tr>
<tr>
<td>Systemic Mycosis</td>
<td>2 (9.5%)</td>
</tr>
<tr>
<td>Endocarditis</td>
<td>1 (4.8%)</td>
</tr>
<tr>
<td>Mediastinitis</td>
<td>1 (4.8%)</td>
</tr>
<tr>
<td>Mean arterial pressure (mmHg)</td>
<td>78 (58-108)</td>
</tr>
<tr>
<td>Heart rate (bpm)</td>
<td>95 (53 - 125)</td>
</tr>
<tr>
<td>Vasopressor support, no.</td>
<td>12 (57.1%)</td>
</tr>
<tr>
<td>Mechanically ventilated, no.</td>
<td>19 (90.5%)</td>
</tr>
<tr>
<td>FiO\textsubscript{2} (%)</td>
<td>40 (25 - 95)</td>
</tr>
<tr>
<td>APACHE II score</td>
<td>22 (12 - 48)</td>
</tr>
<tr>
<td>SOFA score</td>
<td>10 (3 - 19)</td>
</tr>
<tr>
<td>Mortality, no.</td>
<td>11 (52.4%)</td>
</tr>
</tbody>
</table>
METHODS

Subjects

Twenty-one healthy male subjects, mean age 29 (range 19–44) years, were admitted to the research unit of our intensive care unit (Medical Department) at University Medical Center of Groningen, Groningen, The Netherlands. The local Medical Ethics Committee approved the study and written informed consent was obtained. A radial arterial catheter was placed for blood sampling. Thirty minutes before the infusion of LPS, the volunteers received a single oral dose of RWJ-67657 (4-[4-(Fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyrindinyl)-1H-imidazol-2-yl]-3-butyn-1-ol), supplied in an oral pharmaceutical formulation by R. W. Johnson Pharmaceutical Research Institute, Bassersdorf, Switzerland). Three dose levels were tested, placebo-controlled: placebo (n = 6), 350 mg (n = 5), 700 mg (n = 6) and 1400 mg (n = 4). At time point t = 0, LPS (E-Coli, batch EC-6, US Pharmacopeia, Twinbrook Parkway, Rockville, MD, USA) was administered as a 1 min infusion at a dose of 4 ng/kg body weight (10,000 LPS units/mg). Blood samples were drawn at several time points between pre-medication (t = 0) and 24 h after administration of LPS. Samples were placed on ice, centrifuged, stored at -80°C, and analyzed in a blinded fashion.

Patients

The time course of Ang-2 release during the early course of human sepsis was studied in 21 ICU patients (Internal Medicine Department) recruited at Hannover Medical School (tertiary care university hospital), Hannover, Germany. Patient characteristics are shown in table 7.1. Enrollment was performed after obtaining written informed consent from the patient or his/her legal representatives. If the patient was recovering and able to communicate, he/she was informed of the study purpose and consent was required to further maintain status as a study participant. Twenty-eight day survival was the primary outcome studied and was calculated from the day of ICU admission to day of death from any cause. Patients who did not suffer from death within the follow-up were censored at the date of last contact. The study was carried out in accordance with the declaration of Helsinki and was approved by the institutional review board. Serum samples were obtained at baseline (admission), 24h and 72h, placed on ice, centrifuged, stored at
-80°C, and analyzed in a blinded fashion.

**Quantification of circulating Angiopoietin-1 and 2, and soluble Tie2**

Ang-1 and Ang-2 were measured by in-house Immuno Luminometric Assay (ILMA), and Enzyme Linked Immuno Sorbent Assay (ELISA) as published previously in This Journal\textsuperscript{16; 17; 19}. Soluble Tie2 was measured by commercially available ELISA kit (R&D Systems, Oxon, U.K.) according to the manufacturers’ instructions.

![Figure 7.1. Time course of Ang-2, cytokines, and adhesion molecules after LPS challenge in healthy subjects.](image)

(A) Concentrations of circulating Ang-2 compared to plasma levels of TNF-α, IL-6, IL-8, and C-reactive protein after LPS challenge in six healthy volunteers. (B) Concentrations of circulating Ang-2 compared to plasma levels of endothelial adhesion molecules E-selectin, P-selectin, and ICAM-1 after LPS challenge in six healthy volunteers. Non-parametric ANOVA (Friedman’s test) with Dunn’s test for multiple comparison (two sided) was used to demonstrate statistical changes in Ang-2, cytokines, and adhesion molecules (y-axes denote %-increase; baseline = 100%).
### Table 7.2. Time course after LPS challenge in healthy subjects

<table>
<thead>
<tr>
<th>Variables</th>
<th>Pre-Dose</th>
<th>1h</th>
<th>1.5h</th>
<th>2h</th>
<th>2.5h</th>
<th>3.5h</th>
<th>4.5h</th>
<th>6.5h</th>
<th>8h</th>
<th>24h</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systolic BP (mmHg)</td>
<td>140 ± 14</td>
<td>139 ± 11</td>
<td>152 ± 11</td>
<td>158 ± 18</td>
<td>151 ± 18</td>
<td>142 ± 22</td>
<td>121 ± 18</td>
<td>107 ± 11</td>
<td>104 ± 11</td>
<td>131 ± 11</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Diastolic BP (mmHg)</td>
<td>74 ± 10</td>
<td>74 ± 7</td>
<td>80 ± 7</td>
<td>77 ± 12</td>
<td>65 ± 12</td>
<td>61 ± 14</td>
<td>54 ± 11</td>
<td>55 ± 8</td>
<td>55 ± 7</td>
<td>66 ± 7</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>MAP (mmHg)</td>
<td>96 ± 11</td>
<td>96 ± 9</td>
<td>104 ± 7</td>
<td>104 ± 13</td>
<td>94 ± 14</td>
<td>88 ± 16</td>
<td>77 ± 13</td>
<td>72 ± 8</td>
<td>71 ± 7</td>
<td>88 ± 7</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Heart rate (bpm)</td>
<td>61 ± 16</td>
<td>59 ± 11</td>
<td>78 ± 19</td>
<td>78 ± 18</td>
<td>92 ± 12</td>
<td>98 ± 8</td>
<td>101 ± 8</td>
<td>97 ± 11</td>
<td>96 ± 13</td>
<td>81 ± 16</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>HR/MAP Index</td>
<td>0.64 ± 0.11</td>
<td>0.62 ± 0.11</td>
<td>0.75 ± 0.17</td>
<td>0.76 ± 0.22</td>
<td>1.01 ± 0.22</td>
<td>1.15 ± 0.26</td>
<td>1.36 ± 0.32</td>
<td>1.36 ± 0.27</td>
<td>1.4 ± 0.22</td>
<td>0.92 ± 0.16</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Body temperature (°C)</td>
<td>35.4 ± 0.38</td>
<td>36.2 ± 0.54</td>
<td>36.4 ± 0.87</td>
<td>37.0 ± 1.04</td>
<td>37.6 ± 1.11</td>
<td>38.5 ± 0.66</td>
<td>38.9 ± 0.53</td>
<td>38.14 ± 0.28</td>
<td>37.9 ± 0.19</td>
<td>36.2 ± 0.29</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>White blood count (10³/µl)</td>
<td>5.5 ± 0.7</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>10.9 ± 1.6</td>
</tr>
<tr>
<td>C-reactive protein (mg/l)</td>
<td>1.1 ± 2.4</td>
<td>0.9 ± 1.8</td>
<td>-</td>
<td>-</td>
<td>1.5 ± 2.4</td>
<td>2.2 ± 2.5</td>
<td>1.1 ± 2.3</td>
<td>1.8 ± 2.8</td>
<td>4.8 ± 2.0</td>
<td>60.0 ± 21.5</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Ang-1 (ng/ml)</td>
<td>67.0 ± 20.7</td>
<td>58.2 ± 24.4</td>
<td>-</td>
<td>-</td>
<td>61.2 ± 25.0</td>
<td>54.3 ± 19.5</td>
<td>-</td>
<td>64.9 ± 29.1</td>
<td>60.3 ± 31.4</td>
<td>52.3 ± 21.6</td>
<td>0.053</td>
</tr>
<tr>
<td>Ang-2 (ng/ml)</td>
<td>0.57 ± 0.50</td>
<td>0.63 ± 0.20</td>
<td>1.04 ± 0.65</td>
<td>1.63 ± 0.89</td>
<td>2.33 ± 0.69</td>
<td>2.35 ± 1.06</td>
<td>2.42 ± 1.32</td>
<td>2.23 ± 1.18</td>
<td>1.61 ± 1.07</td>
<td>1.51 ± 1.03</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Tie2 (ng/ml)</td>
<td>1.34 ± 0.31</td>
<td>1.23 ± 0.29</td>
<td>1.33 ± 0.32</td>
<td>1.53 ± 0.52</td>
<td>1.23 ± 0.20</td>
<td>1.3 ± 0.16</td>
<td>1.31 ± 0.35</td>
<td>1.4 ± 0.3</td>
<td>1.25 ± 0.32</td>
<td>1.43 ± 0.42</td>
<td>0.085</td>
</tr>
</tbody>
</table>

Legend: A non-parametric repeated-measures ANOVA (Friedman's test) was used to test for significant changes of variables during the time course after LPS challenge (placebo group; n=6).

Abbreviations: BP – blood pressure; HR/MAP index - heart rate/mean arterial pressure index.
Quantification of soluble endothelial-adhesion molecules and cytokines

Soluble ICAM-1, E-selectin, and P-selectin were measured using Fluorokine® MultiAnalyte Profiling kits and a Luminex® Bioanalyzer (R&D Systems, Oxon, U.K.) according to the manufacturers’ instructions. Tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), interleukin-8 (IL-8) and c-reactive protein (CRP) were determined using MEDIGENIX EASIA kits from BioSource (BioSource, Nivelles, Belgium) and reported previously.

Statistical Analysis

The modified Kolmogorov-Smirnov test was used to test for a normal distribution of continuous variables. In the human endotoxemia model, a non-parametric ANOVA (Friedman’s test) with Dunn’s test for multiple comparison (two sided) was used to demonstrate statistical changes in Ang-2, cytokines, and adhesion molecules. Correlations of Ang-2 with TNF-α, E-selectin, and the heart rate/mean arterial pressure index were calculated with Pearson’s correlation and linear regression analysis after log-transformation. Data are presented as mean ± SEM unless otherwise stated.

In patients, differences between survivors and non-survivors at baseline and during follow-up were compared by non-parametric two-sided Mann Whitney test. Receiver Operator Characteristic (ROC) procedures identified optimal cut-off values for Ang-2 to differentiate between survivors and non-survivors. Contingency table-derived data and likelihood ratios were calculated using the StatPages website. Two-sided p-values <0.05 were considered statistically significant for all statistical procedures used. All statistical analyses were performed using the SPSS package (SPSS Inc., Chicago, IL, USA) and the GraphPad Prism software (GraphPad Prism Software Inc. San Diego, California, USA).

RESULTS

Angiopoietin-2 is released in a distinctive pattern after endotoxin challenge in healthy volunteers

Normal Ang-2 concentrations (0.57 ± 0.20 ng/mL) were present at baseline in healthy volunteers (table 7.2). Ang-2 levels started to increase at 2 h, were significantly elevated from 2.5 h until 6.5 h (<0.01), reaching peak levels (2.42 ± 0.54 ng/mL) 4.5 h after LPS.
Figure 7.2. Correlation of Ang-2 with TNF-α, E-selectin and heart rate/mean arterial pressure index after LPS challenge in healthy subjects.

Dot blots showing the correlation between circulating Ang-2 and (A) plasma levels of TNF-α, (B) plasma levels of the soluble endothelial specific adhesion molecule E-selectin, and (C) the heart rate/mean arterial pressure index (HR/MAP index) at 6.5 h after LPS challenge in 21 subjects (placebo (n=6), and medication groups: 350 mg (n=5), 700 mg (n=6), and 1400 mg (n=4), respectively). Pearson’s correlation coefficient was used after logarithmic transformation of variables (axes denote % increase after logarithmic transformation; baseline = 100%).
Angiopoietin-2 release during endotoxemia and sepsis

Figure 7.3. Time course of Ang-2 in critically ill patients with sepsis.

Dot blots showing the concentration of Ang-2 (ng/ml) in 21 septic on ICU admission, 24 hours and 72 hours after admission, respectively. Of note, median Ang-2 levels increased in non-survivors (p=0.019) (continuous line), but remained unchanged in survivors (p=0.83) (dotted line) during the time course. Mean Ang-2 level was higher in non-survivors (filled circles, n=11) compared to survivors (open circles, n=10) on admission (p=0.032), after 24 hours (p=0.027), and 72 hours (p=0.008) (two-sided Mann-Whitney test).

Angiopoietin-2 release runs in parallel with early pro-inflammatory cytokines and precedes endothelial inflammation after endotoxin challenge

Plasma levels of TNF-α were already significantly elevated at 1½ h (p<0.01) compared to baseline, and 30 minutes earlier compared to Ang-2 and IL-6 (figure 7.1A). IL-8 appeared in the circulation ~30 minutes later than Ang-2 and IL-6. Elevated Ang-2 levels declined more slowly than that of TNF-α, IL-6, and IL-8.

Soluble E-selectin appeared in the circulation later than Ang-2 and E-selectin levels were elevated from 4.5 h until 24 h (all p <0.0001). Similarly, ICAM-1 levels were elevated from 6.5 h until 24 h after LPS infusion (all p <0.0001) (figure 7.1B). However, P-selectin did not increase after endotoxin challenge in the present study (p =0.151).

Angiopoietin-2 release after endotoxin challenge is attenuated by p38 MAPK inhibition

Our previous studies have shown that inhibition of the intracellular p38 MAPK attenuated inflammatory responses during human endotoxemia. Thus, we hypothesized that p38 MAPK inhibition would also have an impact on Ang-2 release. In addition to LPS treated subjects that received placebo (n=6, see above), circulating Ang-2 was...
determined in LPS treated subjects that were randomized to different doses of an oral p38 MAPK inhibitor. In contrast to the placebo group (LPS without p38 MAPK inhibitor), no statistically significant Ang-2 release occurred in any of the three interventional groups (i.e. 350 mg, 700 mg, or 1400 mg of RWJ-67657, respectively). However, when the areas under the curves (AUC) during the time course were calculated, a dose dependent effect of RWJ-67657 on Ang-2 release was present.

The AUC of absolute Ang-2 values (ng/ml) were 39.8, 31.0, 32.1, and 17.8 in the placebo and the three interventional groups, respectively. Correspondingly, the AUC of %-increase in Ang-2 from baseline were 9850, 4765, 3435, and 2567 in the placebo and the three interventional groups, respectively).

Circulating Angiopoietin-2 correlates with TNF-alpha levels, soluble E-selectin levels, and the heart rate/mean arterial pressure index

TNF-α levels correlated well with Ang-2 at 3.5 (r =0.44, p =0.04), 4.5 h (r =0.54, p =0.012), 6.5 h (r =0.61, p =0.003), and 8 h (r =0.49, p =0.024) (figure 7.2A). Likewise, levels of soluble E-selectin were closely associated with Ang-2 at 4.5 h (r =0.5, p =0.005), 6.5 h (r =0.64, p =0.0013), and 24 h (r =0.69, p <0.0004) (figure 7.2B), when all subjects in the endotoxin model were analyzed (n=21). Finally, we analyzed the increase in heart rate (HR)/mean arterial pressure (MAP) index as a dynamic surrogate marker of hemodynamic compromise. Indeed, a close correlation was found between the increase in circulating Ang-2 and the increase in HR/MAP index at 4.5 h (r =0.6, p =0.003), 6.5 h (r =0.58, p =0.006), and 8 h (r =0.75, p <0.0001) (figure 7.2C), when all subjects were analyzed (n=21).

Excess Ang-2 on admission and increasing Ang-2 level during the early course indicate unfavorable 28-day survival in septic patients

First, circulating Ang-2 on admission was 9.8 ± 3.2 ng/ml in septic patients (n=21). Regarding the kinetics of Ang-2 during follow-up, mean Ang-2 levels remained unchanged at 24h (14.3 ± 4.0 ng/ml) and 72h (18.2 ± 6.0 ng/ml) when all patients were analyzed (non-parametric repeated measures ANOVA (Friedman’s test); p=0.146) (figure 7.3). Second, when analyzed separately, non-survivors (n=11) had higher Ang-2 levels compared to survivors (n=10) on admission (9.7 ± 1.6 ng/ml vs. 4.7 ± 1.3 ng/ml; p=0.032), after 24h
Ang-2 release during endotoxemia and sepsis

(13.3 ± 3.2 ng/ml vs. 5.0 ± 1.3 ng/ml; p=0.027) and 72h (21.5 ± 6.0 ng/ml vs. 4.3 ±
1.6 ng/ml; p=0.008). In non-survivors, Ang-2 levels were significantly increased after
72h (9.7 ± 1.6 ng/ml vs. 21.5 ± 6.0 ng/ml; p=0.019). In contrast, no increase in Ang-2
level was detected in survivors during follow-up (4.7 ± 1.3 ng/ml vs. 4.3 ± 1.6 ng/ml;
p=0.83) (figure 7.3). Last, we calculated sensitivity, specificity and predictive values by
2 x 2 tables including all patients (n=21) to compare the predictive value between (i)
absolute Ang-2 at baseline, (ii) absolute Ang-2 at 72h, and (iii) the decrease/increase
of Ang-2 between baseline and during 72h, respectively. At baseline (admission), a
ROC-optimized Ang-2 cut-off value >5.9 ng/ml best identified non-survivors with 90%
specificity and 81% sensitivity. The positive predictive value was 90% and the negative
predictive value 81%. In patients with Ang-2 values >5.9 ng/ml, the odds ratio (OR) was
40.5 (95% CI 3.7-398.1) for death during 28-day follow-up (Fisher exact test p=0.002).
Essentially the same results were obtained at 72h when a ROC-optimized Ang-2 cut-off
value >5.0 ng/ml was used (Fisher exact test p=0.002). In a similar fashion, albeit with a
lower statistical significance, the Ang-2 time course (as a categorical variable: increase
vs. non-increase in Ang-2 during 72h) identified non-survivors with 81% specificity and
80% sensitivity. The positive predictive value was 81% and the negative predictive value
80%. In patients with increasing Ang-2 values (during 72h), the OR was 18.0 (95% CI 2.2-
144.6) for death during 28-day follow-up (Fisher exact test p=0.009).

**DISCUSSION**

The present study dissects the time course of Ang-2 release after experimental
LPS administration in healthy subjects. The decisive results are: (1) LPS (4 ng/ml) is a
triggering factor for Ang-2 release in vivo; (2) circulating Ang-2 reached peak levels 4 ½ h
after LPS infusion; (3) Ang-2 exhibited a kinetic profile similar to that of TNF-α, IL-6,
and IL-8, peaked explicitly prior to soluble endothelial-specific adhesion molecules, and
correlated with TNF-α levels, soluble E-selectin levels, and the HR/MAP index; (4) In
septic patients, not only higher baseline Ang-2 but also a persistent increase in Ang-2
predicts unfavorable 28-day survival.

Clinical studies of pathophysiological changes during sepsis are potentially confounded
by the absence of a well-defined onset time of inflammation, by significant co-morbid
Chapter 7

conditions, as well as by considerable delays from the presumed initiation of inflammation until study inclusion. Animal studies, although indispensable for investigating early and late events during systemic inflammation, are potentially confounded by major inter-species differences in the sensitivity and immune response to various types of inflammatory stimuli\textsuperscript{22; 23}. As already indicated, the present study is a re-analysis of blood samples from a placebo-controlled interventional trial on pharmacologic p38 MAP kinase inhibition in endotoxemia. The design of this trial enabled us to investigate the time course of Ang-2 release in humans in a highly standardized experimental model with a graded inflammatory response\textsuperscript{20; 21}.

After LPS infusion, peak Ang-2 levels (2.4 ± 0.5 ng/ml) are 4-fold lower than Ang-2 levels in critically ill patients at the ICU (9.8 ± 3.2 ng/ml). Emerging data from our group, as well as a recent study by Siner et. al\textsuperscript{24} suggest the notion that survival is good in critically ill patients with low Ang-2 (< 7-8 ng/ml), whereas outcome is explicitly worse above this threshold. Indeed, septic patients with circulating Ang-2 levels below 5.9 and 5.0 ng/ml (admission and 72h) identified patients with good 28-day survival in the present study. Compared to the experimental endotoxemia model (single dose of LPS), the inflammatory stimuli in critically illness are probably more intense, often persistent, and multiple in nature. Thus, a rather low but significant Ang-2 peak level of 2.4 ng/ml (4-fold vs. baseline) during experimental endotoxemia is probably adequate and well in line with the aforementioned data. Although we cannot rule out loss of Ang-2 immunoreactivity due to deep-freeze storage for several years, in our experience this phenomenon is negligible\textsuperscript{25}.

Ang-2 exhibited a kinetic profile that is similar to the early pro-inflammatory cytokines TNF-α, IL-6, and IL-8. In the present study, TNF-α level increased somewhat earlier than Ang-2 levels did. As previously shown, the release of TNF-α and several other cytokines during human endotoxemia is blocked by p38 MAPK inhibition in a dose dependent manner\textsuperscript{21}. In the present study, p38 MAPK inhibition blocked Ang-2 release in a similar fashion. In addition, Ang-2 correlated well with TNF-α throughout the time course after LPS infusion. This implies that either the Ang-2 release is mediated by TNF-α, or that a p38-MAP kinase dependent upstream signaling pathway controls both, TNF-α and Ang-2 release. Well in line with this data, Orfanos et al. reported a strong relationship of Ang-2 with TNF-α in critically ill patients, suggesting that the latter may participate in the
regulation of Ang-2 production in sepsis. In contrast, Fiedler et al. showed that even high concentrations of TNF-α are not sufficient to induce Ang-2 release from Human Umbilical Vein Cells (HUVECs) in vitro. However, we cannot exclude that there is an independent route with a slower signaling pathway, and the fact that TNF-α preceded Ang-2 release does not prove causality.

Expression of endothelial adhesion molecules such as E-selectin, VCAM-1, and ICAM-1, are a consistent feature of sepsis. As a functional antagonist of Ang-1/Tie2 signaling, Ang-2 promotes up-regulation of endothelial adhesion molecules (i.e. endothelial activation), by sensitizing endothelial cells toward cytokine-induced adhesion molecule expression. Consistently, firm leukocyte adhesion and subsequent transmigration is almost absent during experimental sepsis in Ang-2 deficient animals. In the present study, Ang-2 levels increased and peaked explicitly prior to soluble endothelial-specific adhesion molecules E-selectin and ICAM-1. Furthermore, soluble E-selectin correlated well with circulating Ang-2 throughout the time course. This temporal sequence is in line with the concept proposed by Fiedler et al. that EC activation might indeed represent a predominantly Ang-2 driven process in vivo.

Although (circulating) Ang-2 has a significant adverse effect on pulmonary vascular barrier properties in sepsis, its role in extra-pulmonary endothelial activation and systemic loss of barrier function is less well defined. However, Ang-1 increases arteriolar vasoconstriction to phenylephrine in the presence of LPS in vitro and preserves blood pressure and cardiac output in septic rats in vivo. Indeed, we found a close correlation between circulating Ang-2 and the HR/MAP as a surrogate marker for hemodynamic compromise in the present study. Although this observation does not prove causality, it is well in line with a significant association of circulating Ang-2 levels with MAP, and vasopressor requirement in a large cohort of critically ill patients (Kümpers et al. submitted).

Over the past few years, it has been appreciated that multiple components of WBP, such as Ang-2, P-selectin, and IL-8, are co-stored with von vWF, the major constituent of WPBs. It has been shown that storage of Ang-2 and P-selectin in WPB is mutually exclusive. Interestingly, we detected a selective release of the aforementioned WPB stored mediators: Ang-2 is released first, then IL-8, and P-selectin is not released at all. The phenomenon that some components are selectively released from WPB has already
been show in vitro\(^{31}\) and deserves further attention in in vitro studies of differential regulation of WPB exocytosis.

As a prepackaged constituent of WPB, it is not surprising that Ang-2 levels on admission are increased in response to early endothelial activation in critically ill patients\(^{14, 24, 19}\). Well in line, high Ang-2 levels on admission are associated with unfavorable 28-day survival. However, it still remained unanswered whether Ang-2 levels either decline, or even increase during the course of sepsis, as recently summarized by Giuliano and Wheeler in this Journal\(^{32}\).

In vitro, intracellular Ang-2 pools are rapidly replenished after stimulated depletion with a PKC activator (phorbol 12-myristate 13-acetate)\(^{27}\). Furthermore, LPS administration has been shown to increase Ang-2 in a murine sepsis model\(^{13}\). Based on available data we hypothesized that levels of circulating Ang-2 might even increase in patients with persistent inflammation and/or clinical deterioration. Indeed, in our cohort of septic patients, non-survivors, not only presented with higher admission Ang-2 levels but also showed a significant increase in Ang-2 during a period of 72h. It is tempting to speculate that LPS regulates both, the release of Ang-2 from WPB and the transcriptional induction at the same time. However, additional pre-clinical but also clinical studies are urgently needed to clarify this issue.

Our study has several limitations. The human endotoxin model carries a risk of inappropriate extrapolation from experimental findings to the clinical setting. However, this is the only model that renders an opportunity to study the early mechanisms of endothelial activation during a time course in human subjects. Since von Willebrand Factor (vWF) (as the major constituent of WPBs) was not determined in this study, and citrated plasma samples from the original trial were not available for re-evaluation, we cannot exclude that Ang-2 might have derived from endothelial cells exclusively. At least murine macrophages seem to express smaller quantities of Ang-2 as well, but this has not been tested in experimental sepsis\(^{34}\). However, the time course of Ang-2 release in the present study was well in line with that of vWF release during endotoxemia\(^{35}\).

Further, the sample size of the septic cohort was small. Thus, ROC procedures and 2 x 2 tables should be interpreted with caution. However, Fisher’s exact test (still appropriate even with small sample size) confirmed the significance of our findings. Finally, elevated circulating Ang-2 is not an exclusive feature of endotoxemia and sepsis, but rather
reflects endothelial activation and vascular damage in diseases that share a significant inflammatory endothelial phenotype\textsuperscript{16, 17, 36}.

CONCLUSIONS

We could show for the first time that LPS administration is a triggering factor for Ang-2 release in men. Circulating Ang-2 appears in the systemic circulation during experimental human endotoxemia in a distinctive temporal sequence and correlates with TNF-\(\alpha\) and E-selectin levels. In addition, not only higher baseline Ang-2 concentrations, but also a persistent increase in Ang-2 during the early course identifies septic patients with unfavorable outcome.

Acknowledgments

We like to thank Dr. Stefan Stuth for extensive monitoring of the patients and Dr. Ulrike Kümpers for critical discussion and proofreading of the manuscript. We also would like to thank Rianne M. Jongman (UMCG, Groningen) for excellent technical assistance.
References


15. Siner JM, Bhandari V, Engle KM, Elias JA, Siegel MD: Elevated serum Angiopoietin 2 levels are associated with increased mortality in sepsis. Shock 2008;

34. Hubbard NE, Lim D, Mukutmoni M, Cai A, Erickson KL: Expression and regulation of
